Sign in
TerminatedPhase 2

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Key facts

Who runs it
Huazhong University of Science and Technology
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
58 people enrolled
Started
3 Apr 2020
Ended
30 Nov 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
  • Albumin-bound Paclitaxel
Record updated
4 November 2024
Why it stopped
slow recruitment forcing early suspension of screening and enrollment

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Age of 18-70 years
  • Second line treatment for cytological or histological diagnosis of recurrent or metastatic gastric and esophagogastric adenocarcinoma. Disease progression after adjuvant therapy within 6 months is eligible
  • ECOG performance status of 0-2
  • Estimated life expectancy of at least 3 months
  • Bone marrow function: white blood cell count≥3.0×109 /L, absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥90×109 /L, hemoglobin(HB) ≥90 g/L
  • Left ventricular ejection fraction (LVEF) ≥ 50%
  • Liver and kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN), or ≤5 x upper limit of normal range (ULN)when with hepatic metastases,total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN), or≤2.5 x upper limit of normal range (ULN) when with Gilbert's syndrome
  • Any acute, clinically significant treatment-related toxicity caused by previous treatment must have been reduced to less than or equal to grade 1, except hair loss
  • Able and willing to comply with the study plans in this protocol and sign the informed consent

Who cannot take part

  • uncontrollable infections or have received systematic antibiotic treatment within 72 hours before enrollment
  • Have a second malignancy within 5 years prior to registration except for cured carcinoma in situ of cervix uteri, non-melanoma skin cancer
  • Live vaccine was administered within 30 days before enrolment (injectable seasonal influenza vaccine is allowed as it is inactivated)
  • Have participated in other clinical trials within 30 days prior to this study
  • Allergic to the chemotherapy drugs or the materials in this study
  • Suffering from mental or nervous system disorders and unable to cooperate
  • Active autoimmune disease, history of autoimmune disease, use of corticosteroids or immunosuppressants, or use of hormone replacement therapy, such as thyroxine, insulin, etc
  • Patients with other diseases not suitable for enrolment, such as active tuberculosis, hepatitis B (after treatment, hepatitis B virus titer HBV-DNA <500IU/ml, and liver function is normal, but cannot be combined with hepatitis C), hepatitis C, uncontrolled electrolyte disorders ,pericardial effusion, pleural effusion and abdominal effusion, etc
  • History of organ transplantation
  • Pregnant or nursing female patients. Men and women of reproductive age are unwilling to take reliable contraceptive measures during the study
  • Any abnormal bone marrow hyperplasia or other abnormal hematopoietic function
  • Patients with symptomatic brain metastases
  • Patients that researcher consider cannot sign informed consent or complete the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

The 2 groups in the trial

  • Nab-P/PD-1Treatment being tested

    Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.

    Treatment: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)

  • Nab-PExisting treatment, for comparison

    Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.

    Treatment: Albumin-bound Paclitaxel

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Open-label, Randomized Controlled Clinical Study of Nab-paclitaxel Plus SHR-1210(PD-1 Inhibitor)Versus Nab-paclitaxel As Second-line Treatment in Advanced or Recurrent Gastric and Esophagogastric Adenocarcinoma
Publications
Record updated
4 November 2024